Jae Hee park - Academia.edu (original) (raw)

Papers by Jae Hee park

Applied Biochemistry and Biotecnology, 2007

Hydrogels are materials with the ability to swell in water through the retention of significant f... more Hydrogels are materials with the ability to swell in water through the retention of significant fractions of water within their structures. Owing to their relatively high degree of biocompatibility, hydrogels have been utilized in a host of biomedical applications. In an attempt to determine the optimum conditions for hydrogel synthesis by the free-radical polymerization of sorbitan methacrylate (SMA), the hydrogel used in this study was well polymerized under the following conditions: 50% (w/v) SMA as monomer, 1% (w/w) alpha, alpha'-azo-bis(isobutyro-nitrile) as thermal initiator, and 1% (w/w) ethylene glycol dimethacrylate as cross-liking agent. Under these conditions, the moisture content of the polymerized SMA hydrogel was higher than in the other conditions. Moreover, the moisture content of the poly(SMA) hydrogel was also found to be higher than that of the poly(methyl methacrylate [MMA]) hydrogel. When the Fourier transform-infrared spectrum of poly(SMA) hydrogel was compared with that of poly(MMA) hydrogel, we noted a band at 1735-1730/cm, which did not appear in the Fourier transform-infrared spectrum of poly(MMA). The surface of the poly(SMA) hydrogel was visualized through scanning electron microscopy, and was uniform and clear in appearance.

Journal of medicinal chemistry, Jan 14, 2014

Advances in experimental medicine and biology, 2013

Chronic lymphocytic leukemia (CLL) is the most frequently diagnosed leukemia in the Western world... more Chronic lymphocytic leukemia (CLL) is the most frequently diagnosed leukemia in the Western world, yet remains essentially incurable. Although initial chemotherapy response rates are high, patients invariably relapse and subsequently develop resistance to chemotherapy. For the moment, allogeneic hematopoietic stem cell transplant (allo-HSCT) remains the only potentially curative treatment for patients with CLL, but it is associated with high rates of treatment-related mortality. Immune-based treatment strategies to augment the cytotoxic potential of T cells offer exciting new treatment options for patients with CLL, and provide a unique and powerful spectrum of tools distinct from traditional chemotherapy. Among the most novel and promising of these approaches are chimeric antigen receptor (CAR)-based cell therapies that combine advances in genetic engineering and adoptive immunotherapy.

Blood, Jan 23, 2012

In this issue of Blood, Iland et al report that the addition of arsenic trioxide during induction... more In this issue of Blood, Iland et al report that the addition of arsenic trioxide during induction and consolidation can substantially reduce the amount of chemotherapy and the duration of consolidation to achieve excellent outcomes in patients with newly diagnosed acute promyelocytic leukemia (APL; see figure).

Hematology/oncology clinics of North America, 2011

ALL remains a difficult disease to treat. In the adult setting, most patients will ultimately die... more ALL remains a difficult disease to treat. In the adult setting, most patients will ultimately die of their disease, whereas in the pediatric setting, relapsed and refractory disease remains a therapeutic challenge. Cellular therapy through allo-HSCT remains an option for these patients, and recent advances in alternative forms of allo-HSCT, including unrelated donor transplants, UCB transplants, and haploidentical transplants, have expanded the numbers of patients eligible for allo-HSCT but have not improved outcomes when compared with HLA-matched related allo-HSCTs. In light of this persistent failure, several novel adoptive cellular approaches are being investigated to treat patients with ALL. The use of enriched WT-1–specific donor T cells to treat patients with ALL is currently under investigation in phase I trials at several centers. Treatment of ALL with genetically modified T cells targeted to the CD19 antigen through the expression of a CD19-specific CAR also have entered phase I clinical trials at several centers. Similarly, a clinical trial treating patients with ALL with genetically modified NK cells targeted to the CD19 antigen has recently opened for accrual. Collectively, these ongoing and anticipated trials provide a promising role for adoptive cellular therapies in the treatment of ALL. What remains to be seen is whether this promise will either translate into improved outcomes for these patients or provide significant insights on which to design second-generation adoptive cell therapeutic clinical trials for ALL in the future.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Jan 20, 2015

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Jan 20, 2012

Journal of peptide science : an official publication of the European Peptide Society, 2012

Burns : journal of the International Society for Burn Injuries, 2013

Oncology (Williston Park, N.Y.), 2011

Therapeutic advances in hematology, 2011

The introduction of all-trans retinoic acid (ATRA) in the late 1980s combined with anthracycline-... more The introduction of all-trans retinoic acid (ATRA) in the late 1980s combined with anthracycline-based chemotherapy has revolutionized the prognosis of acute promyelocytic leukemia (APL) with more than 90% complete response rates and cure rates of approximately 80%. The subsequent advent of arsenic trioxide (ATO) in 1990s and progress in the treatment of APL have changed its course from a highly fatal to a highly curable disease. Despite the dramatic improvement in clinical outcome of APL, treatment failure still occurs due most often to early death. Relapse has become increasingly less frequent, most commonly occurring in patients with high-risk disease. A major focus of research for the past decade has been to develop risk-adapted and rationally targeted nonchemotherapy treatment strategies to reduce treatment-related morbidity and mortality to low- and intermediate-risk or older patients while targeting more intensive or alternative therapy to those patients at most risk of relapse. In this review, emerging new approaches to APL treatment with special emhasis on strategies to reduce early deaths, risk-adapted therapy during induction, consolidation and maintenance, as well as an overview of current and future clinical trials in APL will be discussed.

Leukemia & lymphoma, 2014

American journal of hematology, 2007

Engineering of Reconfigurable Systems and Algorithms, 2002

Lecture Notes in Computer Science, 2007

ABSTRACT A biomechanical analysis system, consisting of measurement and analysis subsystems, were... more ABSTRACT A biomechanical analysis system, consisting of measurement and analysis subsystems, were developed and applied in evaluating the physical usability of a kimchi refrigerator. In the system, 3D motion measurement system and force platform system were used in measuring joint positions, ground reaction forces and moments. The systems also includes 3 analysis modules: kinematic, kinetic, and 3DSSPP analyses. Kimchi refrigerator, which is very popular as a specific refrigerator for kimchi, a Korean traditional dish, was evaluated using the system. The refrigerator is designed as a top-cover that makes the users feel uncomfortable in using it, though most people think it is a very useful product. The result showed it is possible to evaluate the physical usability of the refrigerator using the system effectively and reliably.

Lecture Notes in Computer Science, 2007

ABSTRACT This paper presents analysis of the performance on the IEEE 802.11b in the presence of m... more ABSTRACT This paper presents analysis of the performance on the IEEE 802.11b in the presence of multiple IEEE 802.15.4 interferences. To analyze the performance, packet error rate (PER) and throughput are used as performance metrics. The PER is computed by the bit error rate (BER), the collision time and the number of IEEE 802.15.4 interferers in the presence of in-band of the IEEE 802.11b. The throughput of the IEEE 802.11b under multiple IEEE 802.15.4 interferences is obtained from the total IEEE 802.11b packet length received during a specified time. Analytic results of the performance of IEEE 802.11b under multiple IEEE 802.15.4 interferences are verified by simulation results. These results can support coexistence criteria for the IEEE 802.11b and the IEEE 802.15.4.

Science translational medicine, Jan 28, 2014

Hairy cell leukemia (HCL) is a chronic lymphoproliferative disorder characterized by somatic BRAF... more Hairy cell leukemia (HCL) is a chronic lymphoproliferative disorder characterized by somatic BRAFV600E mutations. The malignant cell in HCL has immunophenotypic features of a mature B cell, but no normal counterpart along the continuum of developing B lymphocytes has been delineated as the cell of origin. We find that the BRAFV600E mutation is present in hematopoietic stem cells (HSCs) in HCL patients, and that these patients exhibit marked alterations in hematopoietic stem/progenitor cell (HSPC) frequencies. Quantitative sequencing analysis revealed a mean BRAFV600E-mutant allele frequency of 4.97% in HSCs from HCL patients. Moreover, transplantation of BRAFV600E-mutant HSCs from an HCL patient into immunodeficient mice resulted in stable engraftment of BRAFV600E-mutant human hematopoietic cells, revealing the functional self-renewal capacity of HCL HSCs. Consistent with the human genetic data, expression of BRafV600E in murine HSPCs resulted in a lethal hematopoietic disorder characterized by splenomegaly, anemia, thrombocytopenia, increased circulating soluble CD25, and increased clonogenic capacity of B lineage cells-all classic features of human HCL. In contrast, restricting expression of BRafV600E to the mature B cell compartment did not result in disease. Treatment of HCL patients with vemurafenib, an inhibitor of mutated BRAF, resulted in normalization of HSPC frequencies and increased myeloid and erythroid output from HSPCs. These findings link the pathogenesis of HCL to somatic mutations that arise in HSPCs and further suggest that chronic lymphoid malignancies may be initiated by aberrant HSCs.

Biomedical Optics and 3-D Imaging, 2012

ABSTRACT Three-dimensional imaging of blood vessel using integral imaging technique is proposed. ... more ABSTRACT Three-dimensional imaging of blood vessel using integral imaging technique is proposed. With a near infrared illumination, a finger is imaged through a lens array and three-dimensional structure of the blood vessel in the finger is visualized.

Applied Biochemistry and Biotecnology, 2007

Hydrogels are materials with the ability to swell in water through the retention of significant f... more Hydrogels are materials with the ability to swell in water through the retention of significant fractions of water within their structures. Owing to their relatively high degree of biocompatibility, hydrogels have been utilized in a host of biomedical applications. In an attempt to determine the optimum conditions for hydrogel synthesis by the free-radical polymerization of sorbitan methacrylate (SMA), the hydrogel used in this study was well polymerized under the following conditions: 50% (w/v) SMA as monomer, 1% (w/w) alpha, alpha'-azo-bis(isobutyro-nitrile) as thermal initiator, and 1% (w/w) ethylene glycol dimethacrylate as cross-liking agent. Under these conditions, the moisture content of the polymerized SMA hydrogel was higher than in the other conditions. Moreover, the moisture content of the poly(SMA) hydrogel was also found to be higher than that of the poly(methyl methacrylate [MMA]) hydrogel. When the Fourier transform-infrared spectrum of poly(SMA) hydrogel was compared with that of poly(MMA) hydrogel, we noted a band at 1735-1730/cm, which did not appear in the Fourier transform-infrared spectrum of poly(MMA). The surface of the poly(SMA) hydrogel was visualized through scanning electron microscopy, and was uniform and clear in appearance.

Journal of medicinal chemistry, Jan 14, 2014

Advances in experimental medicine and biology, 2013

Chronic lymphocytic leukemia (CLL) is the most frequently diagnosed leukemia in the Western world... more Chronic lymphocytic leukemia (CLL) is the most frequently diagnosed leukemia in the Western world, yet remains essentially incurable. Although initial chemotherapy response rates are high, patients invariably relapse and subsequently develop resistance to chemotherapy. For the moment, allogeneic hematopoietic stem cell transplant (allo-HSCT) remains the only potentially curative treatment for patients with CLL, but it is associated with high rates of treatment-related mortality. Immune-based treatment strategies to augment the cytotoxic potential of T cells offer exciting new treatment options for patients with CLL, and provide a unique and powerful spectrum of tools distinct from traditional chemotherapy. Among the most novel and promising of these approaches are chimeric antigen receptor (CAR)-based cell therapies that combine advances in genetic engineering and adoptive immunotherapy.

Blood, Jan 23, 2012

In this issue of Blood, Iland et al report that the addition of arsenic trioxide during induction... more In this issue of Blood, Iland et al report that the addition of arsenic trioxide during induction and consolidation can substantially reduce the amount of chemotherapy and the duration of consolidation to achieve excellent outcomes in patients with newly diagnosed acute promyelocytic leukemia (APL; see figure).

Hematology/oncology clinics of North America, 2011

ALL remains a difficult disease to treat. In the adult setting, most patients will ultimately die... more ALL remains a difficult disease to treat. In the adult setting, most patients will ultimately die of their disease, whereas in the pediatric setting, relapsed and refractory disease remains a therapeutic challenge. Cellular therapy through allo-HSCT remains an option for these patients, and recent advances in alternative forms of allo-HSCT, including unrelated donor transplants, UCB transplants, and haploidentical transplants, have expanded the numbers of patients eligible for allo-HSCT but have not improved outcomes when compared with HLA-matched related allo-HSCTs. In light of this persistent failure, several novel adoptive cellular approaches are being investigated to treat patients with ALL. The use of enriched WT-1–specific donor T cells to treat patients with ALL is currently under investigation in phase I trials at several centers. Treatment of ALL with genetically modified T cells targeted to the CD19 antigen through the expression of a CD19-specific CAR also have entered phase I clinical trials at several centers. Similarly, a clinical trial treating patients with ALL with genetically modified NK cells targeted to the CD19 antigen has recently opened for accrual. Collectively, these ongoing and anticipated trials provide a promising role for adoptive cellular therapies in the treatment of ALL. What remains to be seen is whether this promise will either translate into improved outcomes for these patients or provide significant insights on which to design second-generation adoptive cell therapeutic clinical trials for ALL in the future.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Jan 20, 2015

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Jan 20, 2012

Journal of peptide science : an official publication of the European Peptide Society, 2012

Burns : journal of the International Society for Burn Injuries, 2013

Oncology (Williston Park, N.Y.), 2011

Therapeutic advances in hematology, 2011

The introduction of all-trans retinoic acid (ATRA) in the late 1980s combined with anthracycline-... more The introduction of all-trans retinoic acid (ATRA) in the late 1980s combined with anthracycline-based chemotherapy has revolutionized the prognosis of acute promyelocytic leukemia (APL) with more than 90% complete response rates and cure rates of approximately 80%. The subsequent advent of arsenic trioxide (ATO) in 1990s and progress in the treatment of APL have changed its course from a highly fatal to a highly curable disease. Despite the dramatic improvement in clinical outcome of APL, treatment failure still occurs due most often to early death. Relapse has become increasingly less frequent, most commonly occurring in patients with high-risk disease. A major focus of research for the past decade has been to develop risk-adapted and rationally targeted nonchemotherapy treatment strategies to reduce treatment-related morbidity and mortality to low- and intermediate-risk or older patients while targeting more intensive or alternative therapy to those patients at most risk of relapse. In this review, emerging new approaches to APL treatment with special emhasis on strategies to reduce early deaths, risk-adapted therapy during induction, consolidation and maintenance, as well as an overview of current and future clinical trials in APL will be discussed.

Leukemia & lymphoma, 2014

American journal of hematology, 2007

Engineering of Reconfigurable Systems and Algorithms, 2002

Lecture Notes in Computer Science, 2007

ABSTRACT A biomechanical analysis system, consisting of measurement and analysis subsystems, were... more ABSTRACT A biomechanical analysis system, consisting of measurement and analysis subsystems, were developed and applied in evaluating the physical usability of a kimchi refrigerator. In the system, 3D motion measurement system and force platform system were used in measuring joint positions, ground reaction forces and moments. The systems also includes 3 analysis modules: kinematic, kinetic, and 3DSSPP analyses. Kimchi refrigerator, which is very popular as a specific refrigerator for kimchi, a Korean traditional dish, was evaluated using the system. The refrigerator is designed as a top-cover that makes the users feel uncomfortable in using it, though most people think it is a very useful product. The result showed it is possible to evaluate the physical usability of the refrigerator using the system effectively and reliably.

Lecture Notes in Computer Science, 2007

ABSTRACT This paper presents analysis of the performance on the IEEE 802.11b in the presence of m... more ABSTRACT This paper presents analysis of the performance on the IEEE 802.11b in the presence of multiple IEEE 802.15.4 interferences. To analyze the performance, packet error rate (PER) and throughput are used as performance metrics. The PER is computed by the bit error rate (BER), the collision time and the number of IEEE 802.15.4 interferers in the presence of in-band of the IEEE 802.11b. The throughput of the IEEE 802.11b under multiple IEEE 802.15.4 interferences is obtained from the total IEEE 802.11b packet length received during a specified time. Analytic results of the performance of IEEE 802.11b under multiple IEEE 802.15.4 interferences are verified by simulation results. These results can support coexistence criteria for the IEEE 802.11b and the IEEE 802.15.4.

Science translational medicine, Jan 28, 2014

Hairy cell leukemia (HCL) is a chronic lymphoproliferative disorder characterized by somatic BRAF... more Hairy cell leukemia (HCL) is a chronic lymphoproliferative disorder characterized by somatic BRAFV600E mutations. The malignant cell in HCL has immunophenotypic features of a mature B cell, but no normal counterpart along the continuum of developing B lymphocytes has been delineated as the cell of origin. We find that the BRAFV600E mutation is present in hematopoietic stem cells (HSCs) in HCL patients, and that these patients exhibit marked alterations in hematopoietic stem/progenitor cell (HSPC) frequencies. Quantitative sequencing analysis revealed a mean BRAFV600E-mutant allele frequency of 4.97% in HSCs from HCL patients. Moreover, transplantation of BRAFV600E-mutant HSCs from an HCL patient into immunodeficient mice resulted in stable engraftment of BRAFV600E-mutant human hematopoietic cells, revealing the functional self-renewal capacity of HCL HSCs. Consistent with the human genetic data, expression of BRafV600E in murine HSPCs resulted in a lethal hematopoietic disorder characterized by splenomegaly, anemia, thrombocytopenia, increased circulating soluble CD25, and increased clonogenic capacity of B lineage cells-all classic features of human HCL. In contrast, restricting expression of BRafV600E to the mature B cell compartment did not result in disease. Treatment of HCL patients with vemurafenib, an inhibitor of mutated BRAF, resulted in normalization of HSPC frequencies and increased myeloid and erythroid output from HSPCs. These findings link the pathogenesis of HCL to somatic mutations that arise in HSPCs and further suggest that chronic lymphoid malignancies may be initiated by aberrant HSCs.

Biomedical Optics and 3-D Imaging, 2012

ABSTRACT Three-dimensional imaging of blood vessel using integral imaging technique is proposed. ... more ABSTRACT Three-dimensional imaging of blood vessel using integral imaging technique is proposed. With a near infrared illumination, a finger is imaged through a lens array and three-dimensional structure of the blood vessel in the finger is visualized.